Precision-based solutions for endometriosis: Integrating immunomics and drug repositioning strategies
review
OA: closed
public-domain-us
AI-generated summary
This review explores the roles of immunomics and drug repositioning in developing precision-based treatments for endometriosis by addressing immune microenvironment dysregulation.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Endometriosis (EMs) is an estrogen-dependent, chronic inflammatory disorder characterized by immune microenvironment dysregulation, a critical factor in its pathogenesis. Despite existing therapies, limitations persist, highlighting the urgent need for innovative treatment strategies. This review explores the roles of immune cell dysfunction, immune evasion, and immunomics in EMs. We emphasize the potential of immune-modulating therapies, anti-inflammatory agents, targeted interventions, and epigenetic modulators in advancing treatment options. Additionally, we propose a drug screening framework based on the immune microenvironment. Integrating these insights with drug repositioning approaches promises to drive EMs therapy toward more tailored, precision-based solutions.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
Source provenance
- europepmc
- last seen: 2026-06-17T06:13:18.893374+00:00
- pubmed
- last seen: 2026-06-17T06:08:56.480395+00:00
- unpaywall
- last seen: 2026-05-11T08:34:28.763810+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine